Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desmetramadol Dose Proportionality and Food Effect Study
NCT04683926Phase 1Completed
- Sponsor
- Syntrix Pharmaceuticals
- Start
- Jan 2021
- Primary completion
- Jan 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of desmetramadol in pain (4 arms), sponsored by Syntrix Pharmaceuticals. Primary endpoints: Area Under the Plasma Concentration-Time Curve from time 0 to 32 hours, Area Under the Plasma Concentration-Time Curve from time 0 to infinity at 32 hours and 1 more. Started Jan 2021; status: completed.
02
Drugs
desmetramadol
03
Conditions
pain
Beyond the preview
Go deeper on NCT04683926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04683926.